Comparative Pharmacology
Head-to-head clinical analysis: AXID versus PEPCID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID versus PEPCID.
AXID vs PEPCID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive, reversible inhibition of histamine at H2-receptors on gastric parietal cells, reducing gastric acid secretion by blocking the H2-receptor-mediated activation of adenylate cyclase and subsequent cAMP production.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion by inhibiting cyclic AMP generation.
300 mg orally once daily at bedtime or 150 mg orally twice daily. Max 300 mg/day.
20 mg orally twice daily or 40 mg orally once daily at bedtime for duodenal ulcer; 40 mg orally once daily at bedtime for gastric ulcer; 20 mg orally once daily for GERD; 20 mg orally twice daily for erosive esophagitis; 20 mg intravenously every 12 hours for hospitalized patients with pathological hypersecretory conditions.
None Documented
None Documented
1.5-2.5 hours (prolonged in renal impairment: up to 4-5 hours if CrCl <20 mL/min)
Terminal elimination half-life: 2.5-3.5 hours in normal renal function; prolonged to 8-10 hours in moderate renal impairment (CrCl 10-50 mL/min) and 15-20 hours in severe impairment (CrCl <10 mL/min); no significant change in hepatic impairment.
Renal (60% unchanged), biliary (30%), fecal (<10%)
Renal: ~65-70% unchanged via tubular secretion (active) and glomerular filtration; hepatic metabolism (S-oxidation) ~30%; fecal: <5%.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist